Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...

Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

This approval by the EC for Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced HCC is valid in all 27 member states of the European Union (EU), as well as ...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...

Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo ® plus Yervoy ® for the first-line ...